Shionogi opens doors to new European headquarters in Amsterdam
A strategic location with world-class collaborations
Shionogi is a 142 year-old Japanese pharmaceutical research company headquartered in Osaka, Japan. The company specialises in the development of treatments for anti-infectious disease and other therapeutic areas. In an opening ceremony conducted by His Excellency Mr. Hidehisa Horinouchi, Ambassador of Japan to the Netherlands in the presence of Dr. Koji Hanasaki, the Shionogi Europe Executive Committee, and all current Amsterdam-based employees, the new office officially opened for business.
Amsterdam was selected as Shionogi’s European base thanks to its thriving life science and health ecosystem and proximity to academic and regulatory bodies:“The decision to open our new headquarters in Amsterdam was an easy one for the business. Amsterdam is a great city with a thriving life science community across both biopharmaceuticals and medical technology. It is renowned for its leading knowledge institutions, public-private partnerships, strategic location and of course the presence of key regulatory bodies such as the European Medicines Agency. The new office adds further strength to Shionogi’s European capabilities, as we continue on our ambitious growth journey” says European CEO of Shionogi, Huw Tippett.
Inspiring medical innovation from the heart of Europe
Amsterdam’s renowned research institutions and innovations in the medical field attract business from all around the world. From research hospital Amsterdam UMC pioneering new ways to discharge patients faster with the help of AI to homegrown funding of research into airborne virus transmission, the city is at the epicentre of defining the next generation of healthcare.
An international outlook and thriving innovation scene have made Amsterdam a destination for forward-looking companies. This is evidenced in the city being selected to host the inaugural HLTH Event in June 2024, focused on bringing Europe’s healthcare ecosystem together to tackle the most complex challenges with innovative solutions.